Agilon Health, Inc.
NYSE:AGLMedical - Care Facilities
+$2.26 today
- Market cap
- $1.52B
- Beta
- 3.04
- P/E (TTM)
- -4.8
- EPS (TTM)
- -$22.50
Volume 0.79M
Average 0.41M
AGL Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Agilon Health, Inc.NYSE: AGL
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q1 FY2026 stock-based compensation of $6.26M fell 62.6% year over year, behind the -23.4% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 34.3% from the prior quarter. Over 3 fiscal years it compounded at +20.1% a year.
Context
- Stock-based compensation amounted to 0.8% of revenue in FY2025, unchanged from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -62.6% toward the trailing-twelve-month pace of -23.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 49.12M USD
- Year-over-year change
- -3.0%
- 4-year CAGR
- -36.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 49.12M | -3.0% |
| FY2024 | 2024-12-31 | 50.66M | -26.9% |
| FY2023 | 2023-12-31 | 69.33M | +144.3% |
| FY2022 | 2022-12-31 | 28.38M | -90.3% |
| FY2021 | 2021-12-31 | 292.39M | — |
Stock-Based Compensation vs competitors
How AGL compares with its peers on the latest reported figures
- AGL's LTM Mar 2026 stock-based compensation of $38.65M is the largest of the 10 companies compared; the peer median is $7.15M.
- Its year-over-year change of -23.4% is the 8th highest of 9, against a peer median of -8.4%.
- Stock-based compensation amounts to 0.7% of revenue for AGL, versus a peer median of 10.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $38.65M | -23.4% | +20.1% | 0.7% | |
| LTM Mar 2026 | $27.05M | -9.3% | -7.2% | 11.4% | |
| LTM Mar 2026 | $15.5M | -21.9% | -3.9% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $12.14M | +60.2% | +336.5% | — |
| LTM Mar 2026 | $8.5M | -48.8% | — | 10.5% | |
| LTM Mar 2026 | $7.15M | -15.9% | +1.9% | — | |
| LTM Feb 2026 | $6.18M | -7.5% | +27.9% | 7.7% | |
| LTM Mar 2026 | $5.99M | +37.2% | +2.3% | — | |
| LTM Mar 2026 | $3.96M | +43865.8% | +2.1% | 101.0% | |
MCTACharming Medical Limited Class A Ordinary Shares | FY2024 | $0 | — | — | 0.0% |
| Peer median (excluding AGL) | $7.15M | -8.4% | +2.1% | 10.5% | |
Competitors are the stored peer set for AGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (406.79M) | (106.86M) | (262.8M) | (260.1M) | (391.35M) |
| Depreciation & Amortization | 14.67M | 13.77M | 20.16M | 24.46M | 28.59M |
| Deferred Income Tax | (3.23M) | 532K | 0 | 0 | 0 |
| Stock-Based Compensation | 292.39M | 28.38M | 69.33M | 50.66M | 49.12M |
| Change in Working Capital | (55.03M) | (59.44M) | (10.07M) | 130.59M | 189.47M |
| Accounts Receivables | (149.04M) | (204.17M) | 0 | (74.58M) | 344.59M |
| Inventory | 149.04M | 0 | 0 | 0 | 0 |
| Accounts Payables | 95.7M | 173.45M | 473.61M | 198.58M | (87.48M) |
| Other Working Capital | (150.72M) | (28.72M) | (483.68M) | 6.59M | (67.64M) |
| Other Non-Cash Items | 9.82M | (7.19M) | 27.18M | (3.39M) | 18.4M |
| Operating Cash Flow | (148.16M) | (130.81M) | (156.2M) | (57.78M) | (105.76M) |
| Capital Expenditures | (13.43M) | (32.66M) | (30.82M) | (13.25M) | (13.24M) |
| Acquisitions (Net) | (1.34M) | 500K | (43.06M) | 0 | 0 |
| Purchases of Investments | (7.1M) | (458.27M) | (114.66M) | (12.01M) | (60.15M) |
| Sales of Investments | 7.1M | 52.55M | 164.04M | 206.92M | 193.87M |
| Other Investing Activities | (75.74M) | (23.75M) | (34.51M) | (41.77M) | (31.87M) |
| Investing Cash Flow | (90.51M) | (444.39M) | (44.02M) | 139.89M | 88.61M |
| Debt Repayment | (19.9M) | (5M) | (5M) | (3.75M) | 0 |
| Common Stock Issued | 1.19B | 33.06M | 11.87M | 1.17M | 0 |
| Common Stock Repurchased | 0 | 0 | (200M) | 0 | (2.99M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (14.74M) | 0 | 11.87M | 0 | 0 |
| Financing Cash Flow | 1.15B | 28.06M | (193.13M) | (2.58M) | (2.99M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 915.73M | (547.14M) | (393.35M) | 79.53M | (20.15M) |
| Free Cash Flow | (161.59M) | (163.47M) | (187.01M) | (71.03M) | (119.01M) |
Agilon Health, Inc.
NYSE:AGL
Intrinsic Alpha fair value
Locked
Current Price
$90.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.